ZYME vs. RNA, ACAD, GPCR, RYTM, TGTX, BHC, INDV, JANX, DCPH, and MRVI
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), Structure Therapeutics (GPCR), Rhythm Pharmaceuticals (RYTM), TG Therapeutics (TGTX), Bausch Health Companies (BHC), Indivior (INDV), Janux Therapeutics (JANX), Deciphera Pharmaceuticals (DCPH), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical preparations" industry.
Zymeworks (NYSE:ZYME) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations.
Zymeworks presently has a consensus price target of $12.67, indicating a potential upside of 39.65%. Avidity Biosciences has a consensus price target of $41.33, indicating a potential upside of 55.39%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Zymeworks.
92.9% of Zymeworks shares are owned by institutional investors. 1.2% of Zymeworks shares are owned by insiders. Comparatively, 3.7% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Avidity Biosciences had 5 more articles in the media than Zymeworks. MarketBeat recorded 9 mentions for Avidity Biosciences and 4 mentions for Zymeworks. Avidity Biosciences' average media sentiment score of 0.93 beat Zymeworks' score of 0.12 indicating that Avidity Biosciences is being referred to more favorably in the news media.
Zymeworks received 149 more outperform votes than Avidity Biosciences when rated by MarketBeat users. Likewise, 68.42% of users gave Zymeworks an outperform vote while only 64.62% of users gave Avidity Biosciences an outperform vote.
Zymeworks has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
Zymeworks has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Zymeworks has a net margin of -249.63% compared to Avidity Biosciences' net margin of -2,103.78%. Zymeworks' return on equity of -28.37% beat Avidity Biosciences' return on equity.
Summary
Zymeworks beats Avidity Biosciences on 11 of the 18 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
